GE Healthcare has announced plans to install its second FlexFactory manufacturing platform for cell therapy, this time at Xiangxue Pharmaceutical’s site in Guangzhou, China.
Cellectis’ third gene-edited, ‘off-the-shelf’ CAR T-cell candidate is set to enter clinical development after the US FDA approved an IND application for UCART22.
AveXis – a Novartis company – has added a manufacturing facility in North Carolina to its site network, where it will make investigational therapies for neurological genetic diseases.
TapImmune would consider a partnership deal with a major pharmaceutical firm in a non-Caucasian country, such as Japan or China, if “very compelling” from a financial standpoint, says CEO.
The US Department of Justice has filed a lawsuit to stop US Stem Cell Clinic from performing autologous stem cell procedures at the request of the US Food and Drug Administration (FDA).
Merck & Co. and Roche have ceased enrolment in separate clinical studies trialling Keytruda and Tecentriq as single therapies, due to a lower rate of survival in patients.
GE Healthcare Life Sciences is expanding powdered cell culture media production in Austria and the US, where it says longer shelf-life and reduced transport costs are driving demand.
Eli Lilly has announced plans to buy AurKa Pharma and its lead oncology compound AK-01, just days after purchasing the immuno-oncology firm Armo Biosciences.
In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.
Agilent's 15,000-square-foot expansion will increase its capacity to meet a growing demand for next-generation sequencing products from its genomics group.
Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.
GE Healthcare Life Sciences has launched an updated, flexible cell processing system designed to rapidly and effectively harvest cells for treatments, including CAR T-cell therapy.
GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.
There is a lack of third-party capabilities in the autologous cell therapy space says the new editor of PharmSource ahead of this year’s Interphex Convention.
Bluebird Bio and Celgene Corporation are collaborating to make a CAR T-cell therapy for patients with relapsed and refractory multiple myeloma in the US.
The US Patent and Trademark Office has granted a notice of allowance for ‘shelf life’ timer technology used to protect time-sensitive biologic materials in transit.
‘Splinter-like’ nanostructures have been developed by researchers in the US to deliver biomolecules straight into patient cells for immune-oncology and gene therapies.
A gene-inserting technology that effectively implants large molecules into cells could help modify T-cells from a patient’s immune system, says researcher.
Draper has designed a microfluidic transduction device (MTD) it claims will help CAR T-cell therapy developers lower costs, up efficiency – and potentially bring manufacturing to the patient’s bedside.
A newly approved patent will allow CEL-SCI to explore using cellular delivery to prevent and treat infectious diseases using its LEAPS technology, the firm says.
Lonza will combine its cell and gene therapy capabilities through four centres of excellence worldwide, following a number of investments in the space.
Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”
Adaptimmune Therapeutics has manufactured the first SPEAR-T cells for a patient at its Navy Yard facility, which will be the primary site for its future manufacturing requirements.
Synpromics will make synthetic promotors for a collaboration with UCL Great Ormond Street Institute of Child Health to develop gene therapies for blood-based disorders.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.
